Clinical Trial Update: A Phase 1/2 Study to Evaluate OTX-2002 in Patients with Hepatocellular Carcinoma and Other Solid Tumor Types Known for Association with the MYC Oncogene [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 study of OTX-2002 in hepatocellular carcinoma and other solid tumors has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• OTX-2002

Snippet

Sponsor: Omega Therapeutics | Conditions: Hepatocellular Carcinoma, Solid Tumor | Phase 1, Phase 2 | Status: TERMINATED